EyePoint Pharmaceuticals, Inc. (EYPT)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about EyePoint Pharmaceuticals, Inc. (EYPT)
Company Performance

Current Price

as of Oct 16, 2024

$11.28

P/E Ratio

N/A

Market Cap

$603.69M

Description

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Metrics

Overview

  • HQWatertown, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerEYPT
  • Price$11.28+14.17%

Trading Information

  • Market Cap$603.69M
  • Float92.49%
  • Average Daily Volume (1m)614,440
  • Average Daily Volume (3m)598,296
  • EPS-$1.80

Company

  • Revenue$50.39M
  • Rev Growth (1yr)4.09%
  • Net Income-$30.83M
  • Gross Margin85.22%
  • EBITDA Margin-360.70%
  • EBITDA-$34.18M
  • EV$205.94M
  • EV/Revenue4.09
  • P/EN/A
  • P/S11.91
  • P/B2.58
Documents
SEC Filings
8-K (2024-09-04)
8-K (2024-08-07)
8-K (2024-06-26)
8-K (2024-06-21)
8-K (2024-05-28)
8-K (2024-05-08)
8-K (2024-05-06)
8-K (2024-03-07)
8-K (2024-03-04)
8-K (2024-01-10)
8-K (2023-12-08)
8-K (2023-12-04)
8-K (2023-11-09)
8-K (2023-11-01)
8-K (2023-10-16)
8-K (2023-09-13)
8-K (2023-09-11)
8-K (2023-08-02)
8-K (2023-07-27)
8-K (2023-07-11)
8-K (2023-07-10)
8-K (2023-06-21)
8-K (2023-06-05)
8-K (2023-05-18)
8-K (2023-05-03)
8-K (2023-03-27)
8-K (2023-03-10)
8-K (2023-03-02)
8-K (2023-01-23)
8-K (2023-01-12)
8-K (2023-01-06)
10-Q (2024-08-08)
10-Q (2024-05-09)
10-Q (2023-11-03)
10-Q (2023-08-04)
10-Q (2023-05-04)
10-K (2024-03-08)
10-K (2023-03-10)
Earnings Calls
Earnings Report 2023Q4
Earnings Report (2023-11-01)
Earnings Report (2023-08-02)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: EyePoint Pharmaceuticals Q3 ($ 7.26, +1.24) (2023-11-01T17:07:24Z)
EyePoint Pharmaceuticals reports Q3 EPS ($0.33) vs FactSet ($0.50) [8 est, ($0.70)-(0.39)] ($6.02, 0.00) (2023-11-01T11:08:18Z)
EyePoint Pharmaceuticals announces presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference 2023 ($5.90, 0.00) (2023-10-30T11:10:07Z)